Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study

• প্রধান লেখক: Stefano Mazza (লেখক), Nicole Piazza O. Sed (লেখক), Francesco Simone Conforti (লেখক), Alberto Fascì (লেখক), Alessandro Rimondi (লেখক), Beatrice Marinoni (লেখক), Valentina Casini (লেখক), Chiara Ricci (লেখক), Francesca Munari (লেখক), Lorena Pirola (লেখক), Pietro Invernizzi (লেখক), Carlo Girelli (লেখক), Guido Lupinacci (লেখক), Luca Pastorelli (লেখক), Flaminia Cavallaro (লেখক), Luca Ferraris (লেখক), Alice Colucci (লেখক), Arnaldo Amato (লেখক), Gian Eugenio Tontini (লেখক), Maurizio Vecchi (লেখক), Gionata Fiorino (লেখক), Flavio Caprioli (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wiley, 2022-01-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Abstract Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and subsequently to SB2 (double switch) in pati...